DEVELOPMENT OF TUMOR MODELS FOR PRECLINICAL INVESTIGATION OF THE NEW TARGET DRUGS AGAINST <i>HER2/NEU</i>
HER2/neu is the one from epidermal growth factor receptors family, which plays the important role in the etiology and pathogenesis of different kind of tumors. The most important significance this receptor has for the breast and ovarian cancer. The drug Herceptin, which are blocking this receptor, has been used at the clinical practice by the patients with breast cancer. The development of the new effective and chip drugs against HER2/neu are perspective now. For testing of these drugs is necessary to have adequate tumor models in vivo. The purpose of this investigation was to receive the tumor models positive of HER2/neu on immunodeficient mice for the preclinical evaluation in vivo of the new drugs against HER2/neu. There are presented the results of subcutaneous transplantation of two human cell lines of breast cancer SKBR3 and ovarian SKOV3 to the mice Balb/c nude breaded in Blokhin Russian Cancer Research Center. So presented the results of HER2/neu testing in the tumor passages in vivo.